A Retrospective Study of COVID-19 Treatments

• Sponsor: ProgenaBiome (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04949230
• Collaborator: (none)
• Enrollment: 300
• Location: 1
• Anticipated Duration (Months): 17.3
• Patients Per Site Per Month: 17.3

Study Details

Study Description

Brief Summary

Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.

Condition or Disease	Intervention/Treatment	Phase
Covid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; COVID-19 Acute Bronchitis; COVID-19 Acute Respiratory Distress Syndrome; COVID-19 Lower Respiratory Infection; SARS-CoV2 Infection; SARS-CoV-2 Acute Respiratory Disease	Other: No Intervention Used

Detailed Description

Subjects who have recovered from COVID-19 will answer questions regarding the severity of their illness, symptoms experienced, what treatment they received, and how long they were ill.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 300 participants
• Observational Model: Case-Only
• Time Perspective: Retrospective
• Official Title: A Retrospective Study to Analyze Efficacy of COVID-19 Treatments
• Actual Study Start Date: Feb 19, 2021
• Anticipated Primary Completion Date: Feb 28, 2022
• Anticipated Study Completion Date: Jul 31, 2022

Arms and Interventions

Arm	Intervention/Treatment
COVID-19 Patients Subjects who have recovered from COVID-19	Other: No Intervention Used; There is no intervention in this study

Outcome Measures

Primary Outcome Measures

1. Survey Response [One hour]

   Answers given by subjects on their recovery from COVID-19

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Months and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study

2. Male or female of 18 years of age or older

3. Diagnosis of COVID-19 infection by RT- PCR

4. Recovery from COVID-19

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ginger Aurella	Ventura	California	United States	93003

Sponsors and Collaborators

• ProgenaBiome

Investigators

• Study Director: Sabine Hazan, MD, ProgenaBiome

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: ProgenaBiome
• ClinicalTrials.gov Identifier: NCT04949230
• Other Study ID Numbers: PRG-051
• First Posted: Jul 2, 2021
• Last Update Posted: Sep 5, 2021
• Last Verified: Sep 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Infections; Communicable Diseases; COVID-19; Respiratory Tract Infections; Bronchitis; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury; Respiration Disorders; Respiratory Tract Diseases

Study Results

No Results Posted as of Sep 5, 2021